Open Access. Powered by Scholars. Published by Universities.®
Zucker School of Medicine at Hofstra/Northwell
Adult;; Aged;; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;; *Body Mass Index;; Breast Neoplasms/chemistry/*drug therapy/*pathology;; Cyclophosphamide/administration & dosage;; Disease-Free Survival;; Doxorubicin/administration & dosage;; Drug Administration Schedule;; Female;; Follow-Up Studies;; Humans;; Kaplan-Meier Estimate;; Lymph Nodes/*pathology;; Lymphatic Metastasis;; Middle Aged;; Neoplasm Recurrence
Articles 1 - 1 of 1
Full-Text Articles in Hematology
Body Mass Index, Pam50 Subtype, And Outcomes In Node-Positive Breast Cancer: Calgb 9741 (Alliance), J. A. Ligibel, C. T. Cirrincione, M. Liu, M. Citron, J. N. Ingle, W. Gradishar, S. Martino, W. Sikov, R. Michaelson, W. T. Barry, +6 Additional Authors
Body Mass Index, Pam50 Subtype, And Outcomes In Node-Positive Breast Cancer: Calgb 9741 (Alliance), J. A. Ligibel, C. T. Cirrincione, M. Liu, M. Citron, J. N. Ingle, W. Gradishar, S. Martino, W. Sikov, R. Michaelson, W. T. Barry, +6 Additional Authors
Journal Articles
BACKGROUND: Obesity at diagnosis is associated with poor prognosis in women with breast cancer, but few reports have been adjusted for treatment factors. METHODS: CALGB 9741 was a randomized trial of dose density and sequence of chemotherapy for node-positive breast cancer. All patients received doxorubicin, cyclophosphamide, and paclitaxel, dosed by actual body weight. Height and weight at diagnosis were abstracted from patient records, and the PAM50 assay was performed from archived specimens using the NanoString platform. Relationships between body mass index (BMI), PAM50, and recurrence-free and overall survival (RFS and OS) were evaluated using proportional hazards regression, adjusting for number …